Immuneering Corporation (IMRX)

NASDAQ: IMRX · IEX Real-Time Price · USD
4.22
+0.03 (0.72%)
Feb 1, 2023, 9:35 AM EST - Market open
0.72%
Market Cap 111.43M
Revenue (ttm) 506,088
Net Income (ttm) -48.05M
Shares Out 26.40M
EPS (ttm) -1.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 681
Open 4.14
Previous Close 4.19
Day's Range 4.14 - 4.22
52-Week Range 3.74 - 16.17
Beta n/a
Analysts Buy
Price Target 17.75 (+320.62%)
Earnings Date Mar 9, 2023

About IMRX

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Imm... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 74
Stock Exchange NASDAQ
Ticker Symbol IMRX
Full Company Profile

Financial Performance

In 2021, Immuneering's revenue was $2.08 million, a decrease of -10.02% compared to the previous year's $2.31 million. Losses were -$33.54 million, 96.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for IMRX stock is "Buy." The 12-month stock price forecast is $17.75, which is an increase of 320.62% from the latest price.

Price Target
$17.75
(320.62% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Immuneering To Present at Guggenheim 2023 Oncology Conference

CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical stage biopharmaceutical company that aims to create medicines for all patients with solid tumors ...

1 day ago - GlobeNewsWire

7 Cheap But Risky Biotech Stocks

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

1 week ago - Barrons

Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations

IMM-1-104 being tested in first all-comers RAS clinical trial believed to be conducted to date

2 months ago - GlobeNewsWire

Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue Estimates

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of -2.08% and 92.17%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s...

2 months ago - Zacks Investment Research

Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the First Patient Expected to be Dosed this Quarter

2 months ago - GlobeNewsWire

Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC

IMM-6-415 Shows Preclinical Activity as a Single Agent in RAF and RAS Mutant Tumors and Enhances PD1 and CTLA4 Checkpoint Blockade

2 months ago - GlobeNewsWire

Immuneering Announces Participation in November Investor Conferences

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS m...

3 months ago - GlobeNewsWire

Immuneering Appoints Leah R. Neufeld as Chief People Officer

CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS m...

3 months ago - GlobeNewsWire

Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS m...

4 months ago - GlobeNewsWire

What Makes Immuneering Corporation (IMRX) a New Buy Stock

Immuneering Corporation (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 months ago - Zacks Investment Research

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Initiation of Phase 1/2a Clinical Trial Expected to Occur in Q4 2022 Initiation of Phase 1/2a Clinical Trial Expected to Occur in Q4 2022

4 months ago - GlobeNewsWire

Wall Street Analysts See a 148% Upside in Immuneering Corporation (IMRX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 148% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questiona...

5 months ago - Zacks Investment Research

Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104

Immuneering (IMRX) files an investigational new drug (IND) application to the FDA to start a phase I/IIa study on IMM-1-104 for the treatment of advanced RAS mutant solid tumors. Stock up.

5 months ago - Zacks Investment Research

Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates ...

5 months ago - GlobeNewsWire

Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 224%: Here's is How to Trade

The consensus price target hints at a 223.5% upside potential for Immuneering Corporation (IMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e...

5 months ago - Zacks Investment Research

Immuneering Announces Participation in September Investor Conferences

CAMBRIDGE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates d...

5 months ago - GlobeNewsWire

Immuneering Corporation (IMRX) Reports Q2 Loss, Misses Revenue Estimates

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 15.38% and 65.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights

IND filing for IMM-1-104, which has displayed broad preclinical pan-KRAS/NRAS activity, expected this quarter; Enrollment of first patient in planned Phase 1/2a clinical trial expected in Q4 2022

6 months ago - GlobeNewsWire

Why This Small-Cap Stock Is Gaining More Than 10% Today?

Chardan has initiated coverage of Immuneering Corp (NASDAQ: IMRX) with a Buy rating and a price target of $18. Immuneering's lead candidate, IMM-1-104, an oral MEK inhibitor, is on track for 3Q22 IND ...

7 months ago - Benzinga

Immuneering Announces Participation in William Blair Biotech Focus Conference 2022

CAMBRIDGE, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates d...

7 months ago - GlobeNewsWire

Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer

8 months ago - GlobeNewsWire

Immuneering Announces Participation in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) --  Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates d...

9 months ago - GlobeNewsWire

Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights

IND filing for IMM-1-104 expected in Q3 2022; Enrollment of the first patient expected in Q4 2022

9 months ago - GlobeNewsWire

Immuneering Announces Participation in Citi's Biopharma VIRTUAL Co-Panel Day

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates de...

9 months ago - GlobeNewsWire

Immuneering Announces Participation in Piper Sandler AI/ML Investor Conference

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates ...

10 months ago - GlobeNewsWire